The MSB clinical pipeline has been decimated.
aGVHD is in tatters as the FDA reasonably did not approve on MOA and the attempt to use industry data to prove that failed trials actually succeeded.
ARDS has not passed muster. The result was always going to be impacted by various pretreatment etc.
CHF - primary endpoint failure has left the company with a potential blockbuster that will require someone to understand how it works and to replicate in further clinical trials.
As for CLBP - the science seems a little uncertain given the plethora of failures, inability to prove MOA and left field results.
Novartis has yet to finalise their collaboration. At this point - even if believe in the science makes MSB a complex gamble.
Also this week it seems the acute condition nuance has gently shifted to early stage again.
Novartis deal on the rocks, page-48
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |